Improvement in immune dysfunction after FOLFOX chemotherapy for Stage III colon cancer is associated with improved minimal residual disease prognostic subtype and outcome

Aim Minimal residual disease (MRD) is the net result of the biological properties of disseminated tumour cells and the effect of the immune system and treatment to eliminate them. The aim of this work is to report the changes in MRD status and immune function (lymphocyte count) after FOLFOX chemothe...

Full description

Saved in:
Bibliographic Details
Published in:Colorectal disease 2021-11, Vol.23 (11), p.2879-2893
Main Authors: Murray, Nigel P., Villalon, Ricardo, Hartmann, Dan, Rodriguez, Maria Patricia, Aedo, Socrates
Format: Article
Language:English
Subjects:
Bone marrow
Cell number
Chemotherapy
Colon cancer
Colonic Neoplasms - drug therapy
Colorectal cancer
Disease-Free Survival
Humans
immune dysfunction
Immune response
Immunocytochemistry
Lymphocytes
lymphocytopenia
Minimal residual disease
Neoplasm Recurrence, Local
Neoplasm, Residual
Patients
Prognosis
Prospective Studies
Treatment Outcome
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aim Minimal residual disease (MRD) is the net result of the biological properties of disseminated tumour cells and the effect of the immune system and treatment to eliminate them. The aim of this work is to report the changes in MRD status and immune function (lymphocyte count) after FOLFOX chemotherapy, and the outcome in Stage III colon cancer patients. Method This study is a prospective, single‐centre observational study. Lymphocyte counts were determined prior to and 1, 2 and 3 months after the completion of chemotherapy. Circulating tumour cells (CTCs) and bone marrow micrometastases were determined using immunocytochemistry with anticarcinoembryonic antigen prior to and 1 month after chemotherapy. MRD was classified as negative (Group I), micrometastasis positive only (Group II) and CTC positive (Group III). Changes in lymphocyte counts and MRD subtype following chemotherapy and relapse‐free progression were analysed. Results Of the total of 185 patients, 83 (44.9%) relapsed. The risk of relapse significantly increased from Groups I to III (p 
ISSN:1462-8910
1463-1318
DOI:10.1111/codi.15899